The week in pharma: action, reaction and insight – week to February 24, 2023

26 February 2023

By Barbara Obstoj-Cardwell. Editor

Last week’s important regulatory news included the US Food and Drug Administration (FDA) approving Travere Therapeutics’ Filspari for the reduction of proteinuria in adults with primary IgAN. Among research news, Actinium Pharmaceuticals released positive Phase III data on its myeloid leukemia candidate Iomab-12. On the M&A front, troubled US drug developer Jounce Therapeutics found a ‘white knight’, entering a reverse merger with the UK’s Redx Pharma. Deal-making saw AstraZeneca sign a licensing agreement with China-based KYM Biosciences for CMG901, a potential gastric cancer treatment to expand its own portfolio. Also, having already forked out around $1 billion in upfront and milestone payments, Swiss pharma giant Roche terminated its agreement with US biotech Blueprint Medicines on the cancer drug Gavreto.

Filspari approved with REMS for monthly LFTs in first year

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK